Bristol Myers Squibb disclosed that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial targeting multiple sclerosis, citing septic pneumonia that followed motor symptoms not resolving with standard autoimmune treatments. The event adds to heightened safety attention in autoimmune CAR-T programs after earlier pauses and disclosures by developers. BMS previously paused similar autoimmune studies after observing transient and reversible inflammatory events during routine surveillance. Around the same time, Novartis disclosed deaths in autoimmune CAR-T studies linked to an overactive immune condition. For developers, the central issue is whether dosing, disease-selection criteria, bridging strategies, or management protocols can reduce treatment-related severe inflammatory toxicity while preserving the therapeutic signal. Regulators and investigators are likely to intensify monitoring expectations for immune overactivation in this platform class.